Sex-specific differences in the effects of LDL-c on CVD risk

Media formats available:

Promising results for APOC3 ASO in familial chylomicronemia syndrome
Promising results for APOC3 ASO in familial chylomicronemia syndrome
ACC.24
Promising results for APOC3 ASO in familial chylomicronemia syndrome
- Erik Stroes, MD, PhD
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
ACC.24
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
- Michael Koren, MD
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
ACC.24
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
- Michael Gibson, MD
Characteristics of patients with DM using icosapent ethyl in the real world
Characteristics of patients with DM using icosapent ethyl in the real world
Dyslipidemia
Characteristics of patients with DM using icosapent ethyl in the real world
- Om P. Ganda, MD

PACE-CME